News | December 07, 2022
TTK Healthcare receives a balance amount of Rs. 208.39 Cr from BSV Pharma
TTK Healthcare Limited received from BSV Pharma Pvt. Ltd. a sum of Rs. 593.11 crore on 9th May, 2022
TTK Healthcare Limited received from BSV Pharma Pvt. Ltd. a sum of Rs. 593.11 crore on 9th May, 2022
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
The first use of Philips' breakthrough CavaClear solution to help patients with embedded IVC filters, including an athlete suffering from a 16-year old penetrating filter
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Subscribe To Our Newsletter & Stay Updated
